Literature DB >> 18415210

[Pain relief in the final stage of cancer.].

S Grond1, D Zech, G Horrichs-Haermeyer, K A Lehmann.   

Abstract

Most patients with very advanced cancer suffer from severe pain, and many studies have demonstrated how this pain can be sufficiently controlled. It is of great importance to find out if the findings are also true during the final stage of cancer and how the treatment must be adapted. We therefore examined the methods and efficacy of providing pain relief for dying cancer patients. This study included 160 patients with cancer in different sites. The pain treatment and pain severity during the last few days and hours of their lives are described and discussed. Analgesic drugs administered orally in 53% and parenterally in 39% of the patients were the mainstay of therapy. Non-opioid analgesics alone were effective in 10% and in combination with weak opioids in 15% of the patients. In 68% strong opioids were necessary to achieve sufficient pain reduction. Morphine was the most frequently used opioid for 96 patients. Oral doses of morphine were 86+/-60 mg/day (15-240 mg/day), and parenteral doses 89+/-74 mg/day (15-360 mg/d). Additional adjuvant drugs to treat specific types of pain or other symptoms of cancer disease were described for 80% of the patients. Non-pharmacological measures, such as radiation, nerve blocks or neurosurgery, were of no real importance. Only 4% of the patients treated in the way described experienced severe pain during the final stage of cancer. Systemic administration of drugs is very effective in relieving pain in dying patients. No signs of tolerance to opioids could be observed, even in patients who had been taking opioids for a longer period of time (average 39 days).

Entities:  

Year:  1990        PMID: 18415210     DOI: 10.1007/BF02527826

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  22 in total

1.  A validation study of the WHO method for cancer pain relief.

Authors:  V Ventafridda; M Tamburini; A Caraceni; F De Conno; F Naldi
Journal:  Cancer       Date:  1987-02-15       Impact factor: 6.860

2.  Clinical experience with diamorphine in advanced malignant disease.

Authors:  R G Twycross
Journal:  Int J Clin Pharmacol       Date:  1974-04

3.  Psychotropic drugs.

Authors:  G W Hanks
Journal:  Postgrad Med J       Date:  1984-12       Impact factor: 2.401

4.  Psychopharmacologic applications to cancer. An overview.

Authors:  L R Derogatis
Journal:  Cancer       Date:  1982-11-01       Impact factor: 6.860

5.  Antidepressants in the treatment of cancer pain. A survey in Italy.

Authors:  Guido Magni; Diego Arsie; Diego De Leo
Journal:  Pain       Date:  1987-06       Impact factor: 6.961

Review 6.  Antitumor and antinociceptive approaches to control cancer pain.

Authors:  N Sundaresan; G V DiGiacinto
Journal:  Med Clin North Am       Date:  1987-03       Impact factor: 5.456

7.  Opioid treatment for radiating cancer pain: oral administration vs. epidural techniques.

Authors:  A Vainio; I Tigerstedt
Journal:  Acta Anaesthesiol Scand       Date:  1988-04       Impact factor: 2.105

8.  Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain.

Authors:  S Arnér; B A Meyerson
Journal:  Pain       Date:  1988-04       Impact factor: 6.961

9.  Chronic use of opioid analgesics in non-malignant pain: report of 38 cases.

Authors:  Russell K Portenoy; Kathleen M Foley
Journal:  Pain       Date:  1986-05       Impact factor: 6.961

10.  Home or hospital? Terminal care as seen by surviving spouses.

Authors:  C M Parkes
Journal:  J R Coll Gen Pract       Date:  1978-01
View more
  2 in total

1.  [WHO step II-clinical reality or a didactic instrument?].

Authors:  R Freynhagen; M Zenz; M Strumpf
Journal:  Schmerz       Date:  1994-12       Impact factor: 1.107

2.  [Intractable cancer pain as a reason for referral : Analysis of pain etiology and previous drug treatment.].

Authors:  S Grond; D Zech; H Dahlmann; S A Schug; B Stobbe; K A Lehmann
Journal:  Schmerz       Date:  1990-12       Impact factor: 1.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.